TEVA.TA Teva Pharmaceutical Industries Limited
P/E
55.459457
Forward P/E
37.03971
Price/Sales
6.9049597
Beta
0.875
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Teva Secures Global Rights for Ocrevus Biosimilar, Advancing Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd. and Polpharma Biologics have entered a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab). This...
Teva advances vitiligo drug to Phase 2b, citing 75% facial improvement
Teva Pharmaceutical Industries will advance its anti-IL-15 antibody, TEV-408, into a Phase 2b vitiligo study. The company expects to begin the trial in the...